当前位置: 首页 >> 检索结果
1141. Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.
作者: Michelle C Williams.;Ryan Wereski.;Christopher Tuck.;Philip D Adamson.;Anoop S V Shah.;Edwin J R van Beek.;Giles Roditi.;Colin Berry.;Nicholas Boon.;Marcus Flather.;Steff Lewis.;John Norrie.;Adam D Timmis.;Nicholas L Mills.;Marc R Dweck.;David E Newby.; .
来源: Lancet. 2025年405卷10475期329-337页
The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management guided by coronary CT angiography (CCTA) improved the diagnosis, management, and outcome of patients with stable chest pain. We aimed to assess whether CCTA-guided care results in sustained long-term improvements in management and outcomes.
1142. Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study.
作者: Lisa Mumford.;Rachel Hogg.;Adam Taylor.;Peter Lanyon.;Mary Bythell.;Sean McPhail.;Joseph Chilcot.;Gillian Powter.;Graham S Cooke.;Helen Ward.;Helen Thomas.;Stephen P McAdoo.;Liz Lightstone.;Sean H Lim.;Gavin J Pettigrew.;Fiona A Pearce.;Michelle Willicombe.
来源: Lancet. 2025年405卷10475期314-328页
In the UK, booster COVID-19 vaccinations have been recommended biannually to people considered immune vulnerable. We investigated, at a population level, whether the absence of detectable anti-SARS-CoV-2 spike protein IgG antibody (anti-S Ab) following three or more vaccinations in immunosuppressed individuals was associated with greater risks of infection and severity of infection.
1143. Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
作者: Nisha R Acharya.;Athimalaipet V Ramanan.;Alison B Coyne.;Kathryn L Dudum.;Elia M Rubio.;Sydney M Woods.;Catherine M Guly.;Elena Moraitis.;Harry J D Petrushkin.;Kate Armon.;Narman Puvanachandra.;Jessy T Choi.;Daniel P Hawley.;Benjamin F Arnold.; .
来源: Lancet. 2025年405卷10475期303-313页
Adalimumab is an effective treatment for juvenile idiopathic arthritis-associated uveitis. Data are scarce on the effects of discontinuing adalimumab after control of the disease had been reached. We aimed to assess efficacy and safety of discontinuing treatment in patients with juvenile idiopathic arthritis-associated uveitis.
|